Onkologie. 2009:3(1):54-61

Breast cancer and subsequent primary malignant neoplasms in the Czech Republic 1976-2005

Edvard Geryk1, Marie Bendová2, Jiří Kozel3
1 Fakultní nemocnice Brno Bohunice
2 GPK 3. LF UK a FNKV Praha
3 PřF MU Brno

The number of multiple cancers were evaluated among 118 546 women diagnosed with a first primary breast cancer during 1976–2005,

of which 10 352 (52.7 %) were initial and 9 309 (47.3 %) subsequent breast cancers, registered as of 17. 10. 2007. There were 17 085 (14.4 %)

women with two, 2 138 (1.8 %) with three and 438 (0.4 %) with four and more primary cancers. The subsequent 8 509 (43.3 %) breast

cacers were the 2nd, 673 (3.4 %) the 3rd, 87 (0.4 %) the 4th and 40 (0.2 %) the 5th till the 12th diagnosis. The numbers of 10 352 primary

breast cancers increased during 1976–1994 and then decreased, numbers of 9 309 subsequent breast cancers increased till 2004. Total

10 352 women, diagnosed in 22.1 % of stage I, 45.5 % of stage II, 17.7 % of stage III, 4.2 % of stage IV and 10.6 % unknown, were followed

11 522 second primary neoplasms of that the most frequent were cancers of breast 27 %, skin 19.4 %, digestive system 17 % and female

genital system 15.5 %. Total 3 112 bilateral breast cancers accounted 2.6 % of 118 546 cases, registered in Czech Cancer Registry. The

average interval between the breast and subsequent cancer were 6 years, the proportion of synchronous and metachronous cancers

were 1 : 5.1. The average survival interval of 10 352 women with breast multiplicities were 8.1 year, of which 35.1 % women survived and

64.9 % died as of 17. 10. 2007.

Keywords: breast cancer, multiple malignant neoplasms, age and geographical distribution, topography, clinical stages, synchronous and metachronous cancers.

Published: March 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Geryk E, Bendová M, Kozel J. Breast cancer and subsequent primary malignant neoplasms in the Czech Republic 1976-2005. Onkologie. 2009;3(1):54-61.
Download citation

References

  1. Konečný M, a kol. Prevalence nádorů v České republice, 1989-2005-2015. PřF MU Brno 2008; 69 s. + CD, ISBN 978-80-903255-2-4.
  2. Geryk E, a kol. Zhoubné novotvary v produktivním věku. Zdravotnictví v ČR 2009; 12(2) v tisku.
  3. Geryk E, kol. Výskyt vícečetných nádorů spojených s karcinomem prsu na jižní Moravě v letech 1976-1996. In: Geryk E, kol. Zhoubné novotvary, jižní Morava 1997 MOÚ Brno 1998; 35-36 s, ISBN 80-902266-3-9.
  4. Vítová V. Způsob určování vícečetných malignit v České republice. Klin. onkol. 2002; 15(3): 106.
  5. Curtis RE, Ron E, Hankey BF, et al. New malignancies following breast cancer. In: New malignancies among cancer survivors: SEER cancer registries 1973-2000. Bethesda (MD), Nat. Canc. Inst. 2006; pp. 181-205.
  6. Dong C, et al. Second primary neoplasms in 633,964 cancer patients in Sweden, 1958-1996. Int. J. Canc. 2001; 93(2): 155-161. Go to original source... Go to PubMed...
  7. Mellemkjaer L, et al. Risk of second cancer among women with breast cancer. Int. J. Canc. 2006; 118(9): 2285-2292. Go to original source... Go to PubMed...
  8. Evans HS, et al. Incidence of multiple primary cancers in a cohort of women diagnosed with breast cancer in southeast England. Br. J. Canc. 2001; 84(3): 435-440. Go to original source... Go to PubMed...
  9. Ewertz M, et al. Second cancer following cancer of the female breast in Denmark, 1943-1980. Natl. Canc. Inst. Monogr. 1985; 68: 325-329.
  10. Daly MB, et al. Breast cancer. In: Neugut AI, et al. Multiple primary cancers. Philadelphia, Lippincott Williams-Wilkins 1999; pp. 303-317.
  11. Darby SC, et al. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: a prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol. 2005; 6(8): 557-565. Go to original source... Go to PubMed...
  12. Chen Y, et al. Epidemiology of contralateral breast cancer. Canc. Epidem. Biomarkers Prev. 1999; 8(1): 855-861.
  13. Metcalfe K, et al. Contralateral breast cancer in BRCA1 abd BRCA2 mutation carriers. J. Clin. Oncol. 2004; 22(12): 2328-2335. Go to original source... Go to PubMed...
  14. Curtis RE, et al. Risk of malignant mixed mullerian tumors after tamoxifen therapy for breast cancer. J. Natl. Canc. Inst. 2004; 96(1): 70-74. Go to original source... Go to PubMed...
  15. Swerdlow AJ, et al. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study. J. Natl. Canc. Inst. 2005; 97(5): 375-384. Go to original source... Go to PubMed...
  16. Petráková K, a kol. Léčebné postupy u karcinomu prsu. Klin. onkol. 2008; 21(4): 131-140. Go to PubMed...
  17. Skovajsová M, a kol. Diagnostika diseminovaného karcinomu prsu - českomoravský radiodiagnostiký názor. Sborník XIII. sympozia Onkologie v gynekologii 2008; 10-11. ISBN 978-80-87086-00-1.
  18. Bendová M. Algoritmus verifikace relapsu u nádorové duplicity. Sborník XIII. sympozia Onkologie v gynekologii 2008; 17-32. ISBN 978-80-87086-00-1.
  19. NCI: Surveillance, epidemiology and end results. Nat. Canc. Inst., assessed Sept. 20, 2007; http://seer.cancer.gov/.
  20. Moolgavkar SH, et al. Two-stage model for carcinogenesis: Epidemiology of breast cancer in females. J. Natl. Canc. Inst., 1980; 65: 559-569.
  21. Moolgavkar SH, et al. A stochastic two-stage model for cancer risk assessment. I. The hazard function and the probability of tumor. Risk. Anal. 1988; 8: 383-392. Go to original source... Go to PubMed...
  22. Sjoblom T, at al. The consensus coding sequences of human breast and colorectal cancers. Science 2006; 314: 268-274. Go to original source... Go to PubMed...
  23. Peto J, et al. High constant incidence in twins and other relatives of women with breast cancer. Nat. Genet. 2000; 26: 411-414. Go to original source... Go to PubMed...
  24. Knudson AG. Mutation and cancer: statistical study of retinoblastoma. Proc. Natl. Acad. Sci. USA 1971; 68: 820-823. Go to original source... Go to PubMed...
  25. Hornsby C, et al. What can we learn from the population incidence of cancer? Armitage and Doll revisited. Lancet Oncology 2007; 8: 1030-1038. Go to original source... Go to PubMed...
  26. Geryk E, a kol. Vícečetné zhoubné novotvary v ČR v letech 1976-2005. ČLČ 2009; 148(6) v tisku.
  27. Parkin DM. Evolution of the population-based cancer registry. Nat. Rev. Canc. 2006; 6: 603-612. Go to original source... Go to PubMed...
  28. Alberts DS. Second cancers are killing us! Canc. Epidemiol. Biomarkers Prev. 2006; 15: 2019. Go to original source... Go to PubMed...




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.